REFERENCIAS

  • 1. Scher RK. Et al. Onychomycosis: Diagnosis and definition of cure. J Am Acad Dermatol. 2007; 56:939-944
  • 2. Laboratorios Galderma S.A., Prospecto Locetar 50mg/ml barniz de uñas medicamentoso. Octubre de 2017
  • 3. Lipner, Shari R, and Richard K Scher.J Am Acad Dermatol. 2019;80(4):835-851.
  • 4. Schaller M et al. Mycoses.2017;60:800-807.
  • 5. Baran R. Kaoukhov A. Topical antifungal drugs for the treatment of onychomicosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol. 2005; 19:21-29
  • 6. Ameen M. et al. British Association of Dermatologists guidelines for the management of onychomicosis Br J Dermatol. 2014; 171: 937-9584.
  • 7. Field LA, Adams BB. Tinea pedis in athletes. Int J Dermatol. 2008;47(5):485-492.
  • 8. Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995 Ene;49(1):103-20.
  • 9. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R; European Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol. 2005 Sep; 19 Suppl 1:8-12.
  • 10. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003 Sep; 149 Suppl 65:1-4.
  • 11. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl nail lacquer - realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol. 1992 Sep;17 Suppl 1:26-8 .
  • 12. Ghannoum M, Sevin K, Sarkany M.Dermatol Ther (Heidelb). 2016 Sep;6(3):451.
  • 13. Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol. 1992;17 Suppl 1:61-70.
  • 14. Endringer Pinto F, Bagger C, Kunze G, et al. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging. Mycoses. 2020;63(8):869-875
  • 15. Polak AM. Preclinical data and mode of action of amorolfine. Clin Exp Dermatol. 1992;17 Suppl 1:8-12
  • 16. Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Dic; 15(6):489-502.
  • 17. Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010; 24:910-15.
  • 18. Yaemsiri S, Hou N, Slining MM, He K. Growth rate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010; 24(4):420-3.
  • 19. Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972-1990